top of page

Prior Presenting Companies

Tuesday, JUNE 16  10:00AM ET

Leveraging proprietary neurodegenerative disease platform and growing body of compelling data to advance the first potential approved treatment for Huntington’s disease
Maurice Zauderer, Ph.D.
President and Chief Executive Officer

Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.

Tuesday, JUNE 16  12:00pM ET

A Targeted Approach to CAR T Cell Therapy
J Eisenberg-0866A1_edited.jpg
Jeffrey F. Eisenberg
Chief Executive Officer

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Tuesday, JUNE 16  2:00pM ET

NYSE American: NAVB
NYSE American: NAVB
Jed A. Latkin
Chief Executive Officer, Chief Financial Officer
and Chief Operating Officer

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

© 2020 Virtual Investor  All rights reserved.
Fireside_Masthead3DAYS_Artboard 2.png
Asset 1.png
Chat_ Circle.png
Enter Chat
bottom of page